Almost 90% of drugs fail in the clinical phases due to lack of clinical efficacy and/or safety issues, illustrating the current pre-clinical phase is far from adequate in screening potential drug candidates. Current state-of-the-art pre-clinical models are either in vitro models including organoids, which are human, but not systemic, or animal models, which are systemic but not human. Both result in a poor predictive value for the clinical phase. What is needed is a pre-clinical model that is both human based and systemic. Chippoids has developed such model and will use it to provide early drug development services for pharmaceutical companies. The Chippoids technology is based on organoid-based human organ models, which are systemically combined on multi-organ-chips via physiological flow. Modeling acute kidney disease in our human, organoid based, systemic kidney-liver in vitro model showed clear responses in the liver, demonstrating the systemic interactions between the two organs. Our model will be employed for safety assessment, and disease modelling for target identification and efficacy testing. This allows more efficient pre-selection of potential drug candidates before entering the pre-clinical phase. As a spin-off of the UMC Utrecht, a dedicated team with years of experience with organoid and organ-on-a-chip models provide an unique organoid-based human systemic solution and has already sparked the interest of a global top-10 pharmaceutical company to engage in a joint development. Upon an initial development phase, which requires a € 1.8 M investment, Chippoids will generate revenue after 1 year, be positive cash flow in the 4th year and an expect increasing annual revenues reaching € 6 M after 6 years.